Anti-HCAR2/ GPR109A/ HCA2 monoclonal antibody

Anti-HCAR2/ GPR109A/ HCA2 antibody for FACS & in-vivo assay

Target products collectionGo to HCAR2/HCAR2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T88185-Ab-1/ GM-Tg-hg-T88185-Ab-2Anti-Human HCAR2 monoclonal antibodyHuman
GM-Tg-rg-T88185-Ab-1/ GM-Tg-rg-T88185-Ab-2Anti-Rat HCAR2 monoclonal antibodyRat
GM-Tg-mg-T88185-Ab-1/ GM-Tg-mg-T88185-Ab-2Anti-Mouse HCAR2 monoclonal antibodyMouse
GM-Tg-cynog-T88185-Ab-1/ GM-Tg-cynog-T88185-Ab-2Anti-Cynomolgus/ Rhesus macaque HCAR2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T88185-Ab-1/ GM-Tg-felg-T88185-Ab-2Anti-Feline HCAR2 monoclonal antibodyFeline
GM-Tg-cang-T88185-Ab-1/ GM-Tg-cang-T88185-Ab-2Anti-Canine HCAR2 monoclonal antibodyCanine
GM-Tg-bovg-T88185-Ab-1/ GM-Tg-bovg-T88185-Ab-2Anti-Bovine HCAR2 monoclonal antibodyBovine
GM-Tg-equg-T88185-Ab-1/ GM-Tg-equg-T88185-Ab-2Anti-Equine HCAR2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T88185-Ab-1/ GM-Tg-hg-T88185-Ab-2; GM-Tg-rg-T88185-Ab-1/ GM-Tg-rg-T88185-Ab-2;
GM-Tg-mg-T88185-Ab-1/ GM-Tg-mg-T88185-Ab-2; GM-Tg-cynog-T88185-Ab-1/ GM-Tg-cynog-T88185-Ab-2;
GM-Tg-felg-T88185-Ab-1/ GM-Tg-felg-T88185-Ab-2; GM-Tg-cang-T88185-Ab-1/ GM-Tg-cang-T88185-Ab-2;
GM-Tg-bovg-T88185-Ab-1/ GM-Tg-bovg-T88185-Ab-2; GM-Tg-equg-T88185-Ab-1/ GM-Tg-equg-T88185-Ab-2
Products NameAnti-HCAR2 monoclonal antibody
Formatmab
Target NameHCAR2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-HCAR2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species HCAR2/ GPR109A/ HCA2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T88185
    Target NameHCAR2
    Gene ID338442,80885,353250,100060366
    Gene Symbol and SynonymsGPR109A,Gpr109b,HCA2,HCAR2,HCAR3,HM74,HM74a,HM74b,mHM74b,NIACR1,Puma-g,PUMAG,rHM74b
    Uniprot AccessionQ8TDS4,Q80Z39
    Uniprot Entry NameHCAR2_HUMAN,HCAR2_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000182782
    Target ClassificationGPCR

    The target: HCAR2, gene name: HCAR2, also named as GPR109A, HCA2, HM74a, HM74b, NIACR1, PUMAG, Puma-g. Predicted to enable nicotinic acid receptor activity. Involved in neutrophil apoptotic process and positive regulation of neutrophil apoptotic process. Located in cell junction and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.